About Ophirex
Ophirex is a company based in Corte Madera (United States) founded in 2015 by Matthew Lewin.. Ophirex has raised $16.48 million across 2 funding rounds from investors including HHS. Ophirex offers products and services including Varespladib. Ophirex operates in a competitive market with competitors including Beijing Kangchen Pharmaceutical, Vins Bio Products, Mediclone Biotech, Mithros Bioscience and VenoMab, among others.
- Headquarter Corte Madera, United States
- Founders Matthew Lewin
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ophirex, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.48 M (USD)
in 2 rounds
-
Latest Funding Round
$1.78 M (USD), Grant
Sep 15, 2023
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ophirex
Ophirex offers a comprehensive portfolio of products and services, including Varespladib. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Blocks lethal snake venom components for immediate treatment
Unlock access to complete
Unlock access to complete
Funding Insights of Ophirex
Ophirex has successfully raised a total of $16.48M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.78 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $1.8M
-
First Round
First Round
(28 Mar 2022)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Grant - Ophirex | Valuation |
investors |
|
| Mar, 2022 | Amount | Series B - Ophirex | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ophirex
Ophirex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ophirex
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ophirex
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ophirex Comparisons
Competitors of Ophirex
Ophirex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beijing Kangchen Pharmaceutical, Vins Bio Products, Mediclone Biotech, Mithros Bioscience and VenoMab, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antivenom drugs and pharmaceutical products are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
Antisera and antitoxins for snake bites and infections are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic kits and therapeutic biologics are manufactured and developed.
|
|
| domain | founded_year | HQ Location |
Develops anti-venom antibodies for medical applications.
|
|
| domain | founded_year | HQ Location |
Develops recombinant humanized antibodies targeted against snake venom.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Ophirex
When was Ophirex founded?
Ophirex was founded in 2015 and raised its 1st funding round 7 years after it was founded.
Where is Ophirex located?
Ophirex is headquartered in Corte Madera, United States. It is registered at Corte Madera, California, United States.
Who is the current CEO of Ophirex?
Nancy J Koch is the current CEO of Ophirex.
Is Ophirex a funded company?
Ophirex is a funded company, having raised a total of $16.48M across 2 funding rounds to date. The company's 1st funding round was a Series B of $16.48M, raised on Mar 28, 2022.
What does Ophirex do?
Ophirex was founded in 2015 and is based in Corte Madera, United States. The company operates in the biotechnology sector, focusing on the development of oral therapies to address snake bite envenomations. Its lead candidate, Varespladib, is designed to inhibit sPLA2, a toxic enzyme found in various snake venoms. Research and drug development activities are centered on improving treatment accessibility in affected regions.
Who are the top competitors of Ophirex?
Ophirex's top competitors include Beijing Kangchen Pharmaceutical, Vins Bio Products and Mediclone Biotech.
What products or services does Ophirex offer?
Ophirex offers Varespladib.
Who are Ophirex's investors?
Ophirex has 1 investor. Key investors include HHS.